Schwab Charles R. 4

What Happened

• Charles R. Schwab, Co‑Chairman and Director of Schwab Charles Corp (SCHW), exercised stock options and sold shares in two batches. On Jan 26, 2026 he exercised 134,895 options at $26.39 (cash paid ~$3.56M) and sold 134,895 shares in the open market for a weighted average price of $103.09 (proceeds ~$13.91M). On Jan 28, 2026 he exercised 44,962 options at $26.39 (cash paid ~$1.19M), then sold 44,962 shares at a weighted average $103.20 (proceeds ~$4.64M) and sold an additional 26,475 shares at a weighted average $103.22 (proceeds ~$2.73M). Total shares acquired by exercise = 179,857; total shares sold = 206,332; total reported sale proceeds ≈ $21.28M. The reported exercises were under the company’s stock plan.

Key Details

• Transaction dates/prices: Exercises on 2026-01-26 and 2026-01-28 at $26.39; open-market sales on 2026-01-26 (WASP $103.09) and 2026-01-28 (WASPs $103.20 and $103.22). Some sale prices were executed in multiple trades (ranges disclosed in footnotes).
• Shares owned after transaction: Not disclosed in this Form 4 filing.
• Notable footnotes: 134,895 and 44,962 shares received on exercise were contributed to a living trust (F1, F3). Sale prices reflect weighted averages across multiple trades; the filer offers to provide trade-by-trade details on request (F2, F4, F5). Options were granted under the 2013 Stock Incentive Plan with standard vesting (F6).
• Timeliness: Form filed Jan 28, 2026 for transactions on Jan 26 and Jan 28; filing appears timely.

Context

• This sequence is effectively a cashless exercise: options were exercised and shares were immediately sold in the open market. The filings include derivative conversion records showing the option-to-share conversion (reported at $0 for the derivative line items).
• Contributions of shares to a living trust are estate/ownership planning actions and do not necessarily indicate a change in market view. The transactions are routine insider reporting of option exercise and subsequent sales, not an explicit endorsement or criticism of the company stock.